Sökning: onr:"swepub:oai:lup.lub.lu.se:3662006b-603d-4d2f-9376-fb09182fe101" >
Associations betwee...
Associations between off-label low-dose olanzapine or quetiapine and cardiometabolic mortality
-
- Berge, Jonas (författare)
- Lund University,Lunds universitet,Psykiatri, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Enheten för klinisk beroendeforskning,Forskargrupper vid Lunds universitet,Psychiatry (Lund),Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine,Clinical addiction research unit,Lund University Research Groups,Malmö Addiction Centre, Region Skåne
-
- Abri, Paul (författare)
- Lund University,Lunds universitet,Enheten för klinisk beroendeforskning,Forskargrupper vid Lunds universitet,Clinical addiction research unit,Lund University Research Groups,Malmö Addiction Centre, Region Skåne
-
- Andell, Pontus (författare)
- Karolinska Institutet,Karolinska Institute,Karolinska University Hospital
-
visa fler...
-
- Movahed, Pouya (författare)
- Lund University,Lunds universitet,Psykiatri, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Psychiatry (Lund),Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine
-
- Ragazan, Dragos C. (författare)
- Lund University,University of British Columbia
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2022
- 2022
- Engelska.
-
Ingår i: Journal of Psychiatric Research. - : Elsevier BV. - 0022-3956 .- 1879-1379. ; 149, s. 352-358
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Olanzapine and quetiapine are routinely used off-label at lower doses, though it remains unclear whether treatment is associated with mortality. Here, we examined the associations between low-dose olanzapine/quetiapine, defined as 5 mg/day of olanzapine equivalents (OE) with cardiometabolic mortality in a population-based, longitudinal cohort of individuals who sought specialized psychiatric services. Through cross-linked Swedish registries, 428,525 individuals without psychotic, bipolar, or cardiometabolic disorders, or previous treatment with antipsychotics or cardiometabolic-related drugs were followed for up to 10.5 years. Extended stratified Cox proportional hazards regressions were employed to estimate the hazard ratios (HR) of cardiometabolic mortality as a function of cumulative OE exposures, adjusted for age, sex, inpatient care, and time-dependent psychiatric diagnoses and treatments. Individuals were followed for a total of 2.1 million person-years. Treatment with olanzapine/quetiapine occurred in 18,317 of the cohort. In total, 2606 cardiometabolic-related deaths occurred. Treatment status (treated vs. untreated) was not significantly associated with cardiometabolic mortality (adjusted HR 0.86, 95% CI 0.64–1.15, P = 0.307). However, compared to no treatment, treatment for <6 months was significantly associated with a reduced risk (adjusted HR 0.56, 95% CI 0.37–0.87, P = 0.010) whereas treatment for 6–12 months was significantly associated with an increased risk (adjusted HR 1.89, 95% CI 1.22–2.92, P = 0.004), but not significantly beyond 12 months. Among those treated, each year exposed to an average 5 mg/day was significantly associated with increased cardiometabolic mortality (adjusted HR 1.45, 95% CI 1.06–1.99, P = 0.019). Overall, low-dose olanzapine/quetiapine treatment was weakly associated with cardiometabolic mortality. Clinicians should consider potential cardiometabolic sequelae at lower doses.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- Cardiometabolic
- Mortality
- Olanzapine
- Quetiapine
- Register
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas